Naringenin is an inhibitor of human serum paraoxonase (PON1): An in vitro study

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 6, 2011, Pages 395-401

  Mahrooz, Abdolkarim ^a   Rashidi, Mohammad Reza ^b   Nouri, Mohammad ^c  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Flavonoids; Inhibition; Kinetic parameters; Naringenin; Serum paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; NARINGENIN;

ARTICLE; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; IC 50; IN VITRO STUDY; KINETICS; SPECTROPHOTOMETRY;

ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; FLAVANONES; HUMANS; HYDROXYQUINOLINES; PHENYLACETATES;

EID: 81255165970     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20490     Document Type: Article

References (34)

1. Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335-1342.
2. Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005;38:153-163.
3. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: A brief review. Naunyn-Schmiedeberg's Arch Pharmacol 2004;369:78-88.
4. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002;3:49-55.
5. Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-419.
6. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: A multifaceted biomolecule. Clin Chim Acta 2009;410:1-12.
7. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009;235:1-9.
8. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-399.
9. Camps J, Marsillach J, Joven J. The paraoxonases: Role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009;46:83-106.
10. Azuma K, Ippoushi K, Ito H, Horie H, Terao J. Enhancing effect of lipids and emulsifiers on the accumulation of quercetin metabolites in blood plasma after the short-term ingestion of onion by rats. Biosci Biotechnol Biochem 2003;67:2548-2555.
11. Lotito SB, Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: Cause, consequence, or epiphenomenon? Free Radic Biol Med 2006;41:1727-1746.
12. Vaya J, Mahmood S, Goldblum A, et al. Inhibition of LDL oxidation by flavonoids in relation to their structure and calculated enthalpy. Phytochemistry 2003;62:89-99.
13. Pietinen P, Rimm EB, Korhonen P, et al. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The alpha-tocopherol, beta carotene cancer prevention study. Circulation 1996;94:2720-2727.
14. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. J Am Med Assoc 1996;275:447-451.
15. Lloyd T, Chinehilli VM, Rollings N, et al. Fruit consumption, fitness, and cardiovascular health in female adolescents: The Penn State Young Women's Health Study. Am J Clin Nutr 1998;67:624-630.
16. Fuhrman B, Aviram M. Preservation of paraoxonase activity by wine flavonoids: Possible role in protection of LDL from lipid peroxidation. Ann N Y Acad Sci 2002;957:321-324.
17. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004;24:851-874.
18. Amaro MI, Rocha J, Vila-Real H, et al. Anti-inflammatory activity of naringin and the biosynthesized naringenin by naringinase immobilized in microstructured materials in a model of DSS-induced colitis in mice. Food Res Int 2009;42:1010-1017.
19. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002;160:425-432.
20. Ustundag B, Bahcecioglu IH, Sahin K, et al. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007;52:2006-2014.
21. Gong M, Garige M, Varatharajalu R, et al. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 2009;379:1001-1004.
22. Gouedard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 2004;24:5209-5222.
23. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
24. Kural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004;15:277-283.
25. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-227.
26. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomics of the paraoxonase (PON1) polymorphisms: Effects of on Pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;54:371-392.
27. Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol 2002;22:1248-1250.
28. Bargota RS, Akhtar M, Biggadike K, Gani D, Allemann RK. Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors. Bioorg Med Chem Lett 2003;13:1623-1626.
29. Josse D, Xie W, Masson P, et al. Tryptophan residue(s) as major components of the human serum paraoxonase active site. Chem Biol Interact 1999;119-120:79-84.
30. Ali MM, Abdelkader MA. The influences of naringin on the oxidative state of rats with streptozotocin-induced acute hyperglycaemia. Z Naturforsch 2004;59c:726-733.
31. Joen S-M, Bok S-H, Jang M-K, et al. Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits. Clin Chim Acta 2002;317:181-190.
32. Lee M-K, Bok S-H, Jeong T-S, et al. Supplementation of naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol-fed rats. Bioorg Med Chem 2002;10:2239-2244.
33. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002;96:67-202.
34. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81:230S-242S.